Cargando…
Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Objective To clarify whether any particular β blocker is superior in patients with heart failure and reduced ejection fraction or whether the benefits of these agents are mainly due to a class effect. Design Systematic review and network meta-analysis of efficacy of different β blockers in heart fai...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546627/ https://www.ncbi.nlm.nih.gov/pubmed/23325883 http://dx.doi.org/10.1136/bmj.f55 |
_version_ | 1782256076692914176 |
---|---|
author | Chatterjee, Saurav Biondi-Zoccai, Giuseppe Abbate, Antonio D’Ascenzo, Fabrizio Castagno, Davide Van Tassell, Benjamin Mukherjee, Debabrata Lichstein, Edgar |
author_facet | Chatterjee, Saurav Biondi-Zoccai, Giuseppe Abbate, Antonio D’Ascenzo, Fabrizio Castagno, Davide Van Tassell, Benjamin Mukherjee, Debabrata Lichstein, Edgar |
author_sort | Chatterjee, Saurav |
collection | PubMed |
description | Objective To clarify whether any particular β blocker is superior in patients with heart failure and reduced ejection fraction or whether the benefits of these agents are mainly due to a class effect. Design Systematic review and network meta-analysis of efficacy of different β blockers in heart failure. Data sources CINAHL(1982-2011), Cochrane Collaboration Central Register of Controlled Trials (-2011), Embase (1980-2011), Medline/PubMed (1966-2011), and Web of Science (1965-2011). Study selection Randomized trials comparing β blockers with other β blockers or other treatments. Data extraction The primary endpoint was all cause death at the longest available follow-up, assessed with odds ratios and Bayesian random effect 95% credible intervals, with independent extraction by observers. Results 21 trials were included, focusing on atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol. As expected, in the overall analysis, β blockers provided credible mortality benefits in comparison with placebo or standard treatment after a median of 12 months (odds ratio 0.69, 0.56 to 0.80). However, no obvious differences were found when comparing the different β blockers head to head for the risk of death, sudden cardiac death, death due to pump failure, or drug discontinuation. Accordingly, improvements in left ventricular ejection fraction were also similar irrespective of the individual study drug. Conclusion The benefits of β blockers in patients with heart failure with reduced ejection fraction seem to be mainly due to a class effect, as no statistical evidence from current trials supports the superiority of any single agent over the others. |
format | Online Article Text |
id | pubmed-3546627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-35466272013-01-17 Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis Chatterjee, Saurav Biondi-Zoccai, Giuseppe Abbate, Antonio D’Ascenzo, Fabrizio Castagno, Davide Van Tassell, Benjamin Mukherjee, Debabrata Lichstein, Edgar BMJ Research Objective To clarify whether any particular β blocker is superior in patients with heart failure and reduced ejection fraction or whether the benefits of these agents are mainly due to a class effect. Design Systematic review and network meta-analysis of efficacy of different β blockers in heart failure. Data sources CINAHL(1982-2011), Cochrane Collaboration Central Register of Controlled Trials (-2011), Embase (1980-2011), Medline/PubMed (1966-2011), and Web of Science (1965-2011). Study selection Randomized trials comparing β blockers with other β blockers or other treatments. Data extraction The primary endpoint was all cause death at the longest available follow-up, assessed with odds ratios and Bayesian random effect 95% credible intervals, with independent extraction by observers. Results 21 trials were included, focusing on atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol. As expected, in the overall analysis, β blockers provided credible mortality benefits in comparison with placebo or standard treatment after a median of 12 months (odds ratio 0.69, 0.56 to 0.80). However, no obvious differences were found when comparing the different β blockers head to head for the risk of death, sudden cardiac death, death due to pump failure, or drug discontinuation. Accordingly, improvements in left ventricular ejection fraction were also similar irrespective of the individual study drug. Conclusion The benefits of β blockers in patients with heart failure with reduced ejection fraction seem to be mainly due to a class effect, as no statistical evidence from current trials supports the superiority of any single agent over the others. BMJ Publishing Group Ltd. 2013-01-16 /pmc/articles/PMC3546627/ /pubmed/23325883 http://dx.doi.org/10.1136/bmj.f55 Text en © Chatterjee et al 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Research Chatterjee, Saurav Biondi-Zoccai, Giuseppe Abbate, Antonio D’Ascenzo, Fabrizio Castagno, Davide Van Tassell, Benjamin Mukherjee, Debabrata Lichstein, Edgar Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title | Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title_full | Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title_fullStr | Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title_full_unstemmed | Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title_short | Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
title_sort | benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546627/ https://www.ncbi.nlm.nih.gov/pubmed/23325883 http://dx.doi.org/10.1136/bmj.f55 |
work_keys_str_mv | AT chatterjeesaurav benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT biondizoccaigiuseppe benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT abbateantonio benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT dascenzofabrizio benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT castagnodavide benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT vantassellbenjamin benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT mukherjeedebabrata benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis AT lichsteinedgar benefitsofbblockersinpatientswithheartfailureandreducedejectionfractionnetworkmetaanalysis |